-
1
-
-
67650407532
-
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans
-
Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
-
(2009)
Science
, vol.325
, pp. 197-201
-
-
Garten, R.J.1
Davis, C.T.2
Russell, C.A.3
Shu, B.4
Lindstrom, S.5
Balish, A.6
-
2
-
-
84872164097
-
The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus
-
Tan A.C., Deliyannis G., Bharadwaj M., Brown L.E., Zeng W., Jackson D.C. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 2013, 91:96-104.
-
(2013)
Immunol Cell Biol
, vol.91
, pp. 96-104
-
-
Tan, A.C.1
Deliyannis, G.2
Bharadwaj, M.3
Brown, L.E.4
Zeng, W.5
Jackson, D.C.6
-
3
-
-
67349182104
-
Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes
-
Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87:300-308.
-
(2009)
Immunol Cell Biol
, vol.87
, pp. 300-308
-
-
Brown, L.E.1
Kelso, A.2
-
4
-
-
78649476854
-
Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development
-
Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010, 7:351.
-
(2010)
Virol J
, vol.7
, pp. 351
-
-
Stanekova, Z.1
Vareckova, E.2
-
5
-
-
84878284641
-
Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses
-
Liu D., Shi W., Shi Y., Wang D., Xiao H., Li W., et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013, 381:1926-1932.
-
(2013)
Lancet
, vol.381
, pp. 1926-1932
-
-
Liu, D.1
Shi, W.2
Shi, Y.3
Wang, D.4
Xiao, H.5
Li, W.6
-
6
-
-
47849097202
-
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization
-
Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
-
(2008)
Nat Immunol
, vol.9
, pp. 847-856
-
-
Hornung, V.1
Bauernfeind, F.2
Halle, A.3
Samstad, E.O.4
Kono, H.5
Rock, K.L.6
-
7
-
-
64049085035
-
Mechanism of action of clinically approved adjuvants
-
Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21:23-29.
-
(2009)
Curr Opin Immunol
, vol.21
, pp. 23-29
-
-
Lambrecht, B.N.1
Kool, M.2
Willart, M.A.3
Hammad, H.4
-
8
-
-
34147181229
-
Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
-
Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007, 25:3554-3560.
-
(2007)
Vaccine
, vol.25
, pp. 3554-3560
-
-
Ninomiya, A.1
Imai, M.2
Tashiro, M.3
Odagiri, T.4
-
9
-
-
84869086842
-
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults
-
Nielsen A.B., Nielsen H.S., Nielsen L., Thybo S., Kronborg G. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Vaccine 2012, 30:7067-7071.
-
(2012)
Vaccine
, vol.30
, pp. 7067-7071
-
-
Nielsen, A.B.1
Nielsen, H.S.2
Nielsen, L.3
Thybo, S.4
Kronborg, G.5
-
10
-
-
84867899922
-
A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine
-
Langley J.M., Frenette L., Chu L., McNeil S., Halperin S., Li P., et al. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infect Dis 2012, 12:279.
-
(2012)
BMC Infect Dis
, vol.12
, pp. 279
-
-
Langley, J.M.1
Frenette, L.2
Chu, L.3
McNeil, S.4
Halperin, S.5
Li, P.6
-
11
-
-
84861963478
-
The mechanism of action of MF59 - an innately attractive adjuvant formulation
-
O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
-
(2012)
Vaccine
, vol.30
, pp. 4341-4348
-
-
O'Hagan, D.T.1
Ott, G.S.2
De Gregorio, E.3
Seubert, A.4
-
12
-
-
84891473026
-
Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients
-
Son J., Lee S.B., Lee D.W., Kim I.Y., Lee S.J., Lee S.M., et al. Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients. Clin Exp Nephrol 2013, 17:275-283.
-
(2013)
Clin Exp Nephrol
, vol.17
, pp. 275-283
-
-
Son, J.1
Lee, S.B.2
Lee, D.W.3
Kim, I.Y.4
Lee, S.J.5
Lee, S.M.6
-
13
-
-
77953125928
-
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
-
Ansaldi F., Zancolli M., Durando P., Montomoli E., Sticchi L., Del Giudice G., et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010, 28:4123-4129.
-
(2010)
Vaccine
, vol.28
, pp. 4123-4129
-
-
Ansaldi, F.1
Zancolli, M.2
Durando, P.3
Montomoli, E.4
Sticchi, L.5
Del Giudice, G.6
-
14
-
-
79952411472
-
Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets
-
van den Brand J.M., Kreijtz J.H., Bodewes R., Stittelaar K.J., van Amerongen G., Kuiken T., et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 2011, 85:2851-2858.
-
(2011)
J Virol
, vol.85
, pp. 2851-2858
-
-
van den Brand, J.M.1
Kreijtz, J.H.2
Bodewes, R.3
Stittelaar, K.J.4
van Amerongen, G.5
Kuiken, T.6
-
15
-
-
77949657463
-
AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice
-
Caillet C., Piras F., Bernard M.C., de Montfort A., Boudet F., Vogel F.R., et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 2010, 28:3076-3079.
-
(2010)
Vaccine
, vol.28
, pp. 3076-3079
-
-
Caillet, C.1
Piras, F.2
Bernard, M.C.3
de Montfort, A.4
Boudet, F.5
Vogel, F.R.6
-
16
-
-
84857482098
-
The importance of adjuvant formulation in the development of a tuberculosis vaccine
-
Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 2012, 188:2189-2197.
-
(2012)
J Immunol
, vol.188
, pp. 2189-2197
-
-
Baldwin, S.L.1
Bertholet, S.2
Reese, V.A.3
Ching, L.K.4
Reed, S.G.5
Coler, R.N.6
-
17
-
-
77958498224
-
Vaccine adjuvants: putting innate immunity to work
-
Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
-
(2010)
Immunity
, vol.33
, pp. 492-503
-
-
Coffman, R.L.1
Sher, A.2
Seder, R.A.3
-
18
-
-
61549132283
-
A universal epitope-based influenza vaccine and its efficacy against H5N1
-
Adar Y., Singer Y., Levi R., Tzehoval E., Perk S., Banet-Noach C., et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009, 27:2099-2107.
-
(2009)
Vaccine
, vol.27
, pp. 2099-2107
-
-
Adar, Y.1
Singer, Y.2
Levi, R.3
Tzehoval, E.4
Perk, S.5
Banet-Noach, C.6
-
19
-
-
84868283459
-
A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years
-
Antrobus R.D., Lillie P.J., Berthoud T.K., Spencer A.J., McLaren J.E., Ladell K., et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012, 7:e48322.
-
(2012)
PLoS One
, vol.7
-
-
Antrobus, R.D.1
Lillie, P.J.2
Berthoud, T.K.3
Spencer, A.J.4
McLaren, J.E.5
Ladell, K.6
-
20
-
-
84862219175
-
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
-
Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55:19-25.
-
(2012)
Clin Infect Dis
, vol.55
, pp. 19-25
-
-
Lillie, P.J.1
Berthoud, T.K.2
Powell, T.J.3
Lambe, T.4
Mullarkey, C.5
Spencer, A.J.6
-
21
-
-
79951645476
-
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
-
Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.
-
(2011)
Clin Infect Dis
, vol.52
, pp. 1-7
-
-
Berthoud, T.K.1
Hamill, M.2
Lillie, P.J.3
Hwenda, L.4
Collins, K.A.5
Ewer, K.J.6
-
22
-
-
0035070198
-
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
-
Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
-
(2001)
Immunity
, vol.14
, pp. 303-313
-
-
Basu, S.1
Binder, R.J.2
Ramalingam, T.3
Srivastava, P.K.4
-
23
-
-
0345305789
-
Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells
-
Berwin B., Hart J.P., Rice S., Gass C., Pizzo S.V., Post S.R., et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J 2003, 22:6127-6136.
-
(2003)
EMBO J
, vol.22
, pp. 6127-6136
-
-
Berwin, B.1
Hart, J.P.2
Rice, S.3
Gass, C.4
Pizzo, S.V.5
Post, S.R.6
-
24
-
-
1942501656
-
Essential role of CD91 in re-presentation of gp96-chaperoned peptides
-
Binder R.J., Srivastava P.K. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Nat Acad Sci USA 2004, 101:6128-6133.
-
(2004)
Proc Nat Acad Sci USA
, vol.101
, pp. 6128-6133
-
-
Binder, R.J.1
Srivastava, P.K.2
-
25
-
-
58749109185
-
Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses
-
De Filippo A., Binder R.J., Camisaschi C., Beretta V., Arienti F., Villa A., et al. Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses. J Immunol 2008, 181:6525-6535.
-
(2008)
J Immunol
, vol.181
, pp. 6525-6535
-
-
De Filippo, A.1
Binder, R.J.2
Camisaschi, C.3
Beretta, V.4
Arienti, F.5
Villa, A.6
-
26
-
-
77955669767
-
High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules
-
Matsutake T., Sawamura T., Srivastava P.K. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun 2010, 10:7.
-
(2010)
Cancer Immun
, vol.10
, pp. 7
-
-
Matsutake, T.1
Sawamura, T.2
Srivastava, P.K.3
-
27
-
-
49149084518
-
Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation
-
Robert J., Ramanayake T., Maniero G.D., Morales H., Chida A.S. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 2008, 180:3176-3182.
-
(2008)
J Immunol
, vol.180
, pp. 3176-3182
-
-
Robert, J.1
Ramanayake, T.2
Maniero, G.D.3
Morales, H.4
Chida, A.S.5
-
28
-
-
33747339222
-
Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses
-
Warger T., Hilf N., Rechtsteiner G., Haselmayer P., Carrick D.M., Jonuleit H., et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 2006, 281:22545-22553.
-
(2006)
J Biol Chem
, vol.281
, pp. 22545-22553
-
-
Warger, T.1
Hilf, N.2
Rechtsteiner, G.3
Haselmayer, P.4
Carrick, D.M.5
Jonuleit, H.6
-
29
-
-
84863115806
-
The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain
-
Wu S., Hong F., Gewirth D., Guo B., Liu B., Li Z. The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain. J Biol Chem 2012, 287:6735-6742.
-
(2012)
J Biol Chem
, vol.287
, pp. 6735-6742
-
-
Wu, S.1
Hong, F.2
Gewirth, D.3
Guo, B.4
Liu, B.5
Li, Z.6
-
30
-
-
33847260278
-
Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages
-
Yang Y., Liu B., Dai J., Srivastava P.K., Zammit D.J., Lefrancois L., et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity 2007, 26:215-226.
-
(2007)
Immunity
, vol.26
, pp. 215-226
-
-
Yang, Y.1
Liu, B.2
Dai, J.3
Srivastava, P.K.4
Zammit, D.J.5
Lefrancois, L.6
-
31
-
-
84859101225
-
Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited
-
Randazzo M., Terness P., Opelz G., Kleist C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012, 130:2219-2231.
-
(2012)
Int J Cancer
, vol.130
, pp. 2219-2231
-
-
Randazzo, M.1
Terness, P.2
Opelz, G.3
Kleist, C.4
-
32
-
-
79951555513
-
Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant
-
Li Y., Song H., Li J., Wang Y., Yan X., Zhao B., et al. Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant. J Biotechnol 2011, 151:343-349.
-
(2011)
J Biotechnol
, vol.151
, pp. 343-349
-
-
Li, Y.1
Song, H.2
Li, J.3
Wang, Y.4
Yan, X.5
Zhao, B.6
-
33
-
-
34547837401
-
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial
-
Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
-
(2007)
Lancet
, vol.370
, pp. 580-589
-
-
Leroux-Roels, I.1
Borkowski, A.2
Vanwolleghem, T.3
Drame, M.4
Clement, F.5
Hons, E.6
-
34
-
-
47749108644
-
A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets
-
Joseph T., McAuliffe J., Lu B., Vogel L., Swayne D., Jin H., et al. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 2008, 378:123-132.
-
(2008)
Virology
, vol.378
, pp. 123-132
-
-
Joseph, T.1
McAuliffe, J.2
Lu, B.3
Vogel, L.4
Swayne, D.5
Jin, H.6
-
35
-
-
79952076763
-
Heat shock protein 70 inhibits the activity of influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo
-
Li G., Zhang J., Tong X., Liu W., Ye X. Heat shock protein 70 inhibits the activity of influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo. PLoS One 2011, 6:e16546.
-
(2011)
PLoS One
, vol.6
-
-
Li, G.1
Zhang, J.2
Tong, X.3
Liu, W.4
Ye, X.5
-
36
-
-
80051569840
-
Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
-
Wang S.F., Qiu L.P., Liu G.Z., Li Y., Zhang X.J., Jin W.S., et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. Vaccine 2011, 29:6342-6351.
-
(2011)
Vaccine
, vol.29
, pp. 6342-6351
-
-
Wang, S.F.1
Qiu, L.P.2
Liu, G.Z.3
Li, Y.4
Zhang, X.J.5
Jin, W.S.6
-
37
-
-
84871645347
-
TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses
-
Zhao B., Wang Y., Zhang Y., Li Y., Zhang X., Xu Y., et al. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses. Vaccine 2013, 31:545-552.
-
(2013)
Vaccine
, vol.31
, pp. 545-552
-
-
Zhao, B.1
Wang, Y.2
Zhang, Y.3
Li, Y.4
Zhang, X.5
Xu, Y.6
-
38
-
-
70449334144
-
Treg suppress CTL responses upon immunization with HSP gp96
-
Liu Z., Li X., Qiu L., Zhang X., Chen L., Cao S., et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 2009, 39:3110-3120.
-
(2009)
Eur J Immunol
, vol.39
, pp. 3110-3120
-
-
Liu, Z.1
Li, X.2
Qiu, L.3
Zhang, X.4
Chen, L.5
Cao, S.6
-
39
-
-
78649395770
-
Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity
-
Hong D.K., Chang S., Botham C.M., Giffon T.D., Fairman J., Lewis D.B. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol 2010, 84:12691-12702.
-
(2010)
J Virol
, vol.84
, pp. 12691-12702
-
-
Hong, D.K.1
Chang, S.2
Botham, C.M.3
Giffon, T.D.4
Fairman, J.5
Lewis, D.B.6
-
40
-
-
77949603728
-
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models
-
Kistner O., Crowe B.A., Wodal W., Kerschbaum A., Savidis-Dacho H., Sabarth N., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:e9349.
-
(2010)
PLoS One
, vol.5
-
-
Kistner, O.1
Crowe, B.A.2
Wodal, W.3
Kerschbaum, A.4
Savidis-Dacho, H.5
Sabarth, N.6
-
41
-
-
79953230918
-
Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development
-
Liu J., Zhang S., Tan S., Zheng B., Gao G.F. Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Exp Biol Med (Maywood) 2011, 236:253-267.
-
(2011)
Exp Biol Med (Maywood)
, vol.236
, pp. 253-267
-
-
Liu, J.1
Zhang, S.2
Tan, S.3
Zheng, B.4
Gao, G.F.5
-
42
-
-
84861480715
-
Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine
-
Atsmon J., Kate-Ilovitz E., Shaikevich D., Singer Y., Volokhov I., Haim K.Y., et al. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol 2012, 32:595-603.
-
(2012)
J Clin Immunol
, vol.32
, pp. 595-603
-
-
Atsmon, J.1
Kate-Ilovitz, E.2
Shaikevich, D.3
Singer, Y.4
Volokhov, I.5
Haim, K.Y.6
-
43
-
-
84871574987
-
Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice
-
Huang B., Wang W., Li R., Wang X., Jiang T., Qi X., et al. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J 2012, 9:322.
-
(2012)
Virol J
, vol.9
, pp. 322
-
-
Huang, B.1
Wang, W.2
Li, R.3
Wang, X.4
Jiang, T.5
Qi, X.6
-
44
-
-
84873349582
-
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus
-
Kim M.C., Song J.M., Eunju O., Kwon Y.M., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21:485-492.
-
(2013)
Mol Ther
, vol.21
, pp. 485-492
-
-
Kim, M.C.1
Song, J.M.2
Eunju, O.3
Kwon, Y.M.4
Lee, Y.J.5
Compans, R.W.6
-
45
-
-
77954409486
-
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus
-
Zhao G., Sun S., Du L., Xiao W., Ru Z., Kou Z., et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 2010, 7:151.
-
(2010)
Virol J
, vol.7
, pp. 151
-
-
Zhao, G.1
Sun, S.2
Du, L.3
Xiao, W.4
Ru, Z.5
Kou, Z.6
-
46
-
-
84870696513
-
Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals
-
Liu J., Zhang S., Tan S., Yi Y., Wu B., Cao B., et al. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals. J Virol 2012, 86:13281-13294.
-
(2012)
J Virol
, vol.86
, pp. 13281-13294
-
-
Liu, J.1
Zhang, S.2
Tan, S.3
Yi, Y.4
Wu, B.5
Cao, B.6
-
47
-
-
70349972479
-
PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants
-
Ichinohe T., Ainai A., Tashiro M., Sata T., Hasegawa H. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009, 27:6276-6279.
-
(2009)
Vaccine
, vol.27
, pp. 6276-6279
-
-
Ichinohe, T.1
Ainai, A.2
Tashiro, M.3
Sata, T.4
Hasegawa, H.5
-
48
-
-
84864492941
-
Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge
-
Wang X., Zhang W., Liu F., Zheng M., Zheng D., Zhang T., et al. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge. Arch Virol 2012, 157:1451-1461.
-
(2012)
Arch Virol
, vol.157
, pp. 1451-1461
-
-
Wang, X.1
Zhang, W.2
Liu, F.3
Zheng, M.4
Zheng, D.5
Zhang, T.6
-
49
-
-
78149457931
-
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
-
Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 2010, 5:e13677.
-
(2010)
PLoS One
, vol.5
-
-
Coler, R.N.1
Baldwin, S.L.2
Shaverdian, N.3
Bertholet, S.4
Reed, S.J.5
Raman, V.S.6
-
50
-
-
77957906849
-
Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice
-
Huang M.H., Lin S.C., Hsiao C.H., Chao H.J., Yang H.R., Liao C.C., et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 2010, 5:e12279.
-
(2010)
PLoS One
, vol.5
-
-
Huang, M.H.1
Lin, S.C.2
Hsiao, C.H.3
Chao, H.J.4
Yang, H.R.5
Liao, C.C.6
-
51
-
-
84899965895
-
Placenta-derived gp96 as a multivalent prophylactic cancer vaccine
-
Zhao B., Wang Y., Wu B., Liu S., Wu E., Fan H., et al. Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Sci Rep 2013, 3:1947.
-
(2013)
Sci Rep
, vol.3
, pp. 1947
-
-
Zhao, B.1
Wang, Y.2
Wu, B.3
Liu, S.4
Wu, E.5
Fan, H.6
-
52
-
-
70449719118
-
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
-
Qian J., Hong S., Wang S., Zhang L., Sun L., Wang M., et al. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 2009, 114:3880-3889.
-
(2009)
Blood
, vol.114
, pp. 3880-3889
-
-
Qian, J.1
Hong, S.2
Wang, S.3
Zhang, L.4
Sun, L.5
Wang, M.6
|